CFO
PRME icon

Callan Family Office’s Prime Medicine PRME Stock Holding History

Callan Family Office’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,292
Closed -$39.2K – 1167
2025
Q4 		$39.2K Buy
+11,292
New +$50.2K ﹤0.01% 1097

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Callan Family Office's PRME Position: Q1 2026 in Review

Callan Family Office sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 11,292 shares — an estimated $39.2K sold.

Callan Family Office first reported a position in PRME in Q4 2025 and held it in 1 quarter. The position peaked at $39.2K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Callan Family Office reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Callan Family Office sold 11,292 Prime Medicine shares in Q1 2026, an estimated $39.2K.
  • Callan Family Office first reported a position in Prime Medicine in Q4 2025 and held it in 1 quarter.
  • Callan Family Office's Prime Medicine position peaked at $39.2K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.